NOT FOR DISTRIBUTION
Header cover image

VentriPoint Diagnostics

Market Cap

CA$57.3m

Last Updated

2021/05/14 22:20 UTC

Data Sources

Company Financials

Executive Summary

Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. More Details


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has VentriPoint Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VPT is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: VPT's weekly volatility has decreased from 23% to 17% over the past year, but is still higher than 75% of Canadian stocks.


Market Performance


7 Day Return

5.7%

VPT

-11.2%

CA Medical Equipment

-0.7%

CA Market


1 Year Return

n/a

VPT

25.0%

CA Medical Equipment

39.3%

CA Market

Return vs Industry: Insufficient data to determine how VPT performed against the Canadian Medical Equipment industry.

Return vs Market: Insufficient data to determine how VPT performed against the Canadian Market.


Shareholder returns

VPTIndustryMarket
7 Day5.7%-11.2%-0.7%
30 Day-9.8%-13.5%1.0%
90 Day2.2%-28.2%6.1%
1 Yearn/a25.0%25.0%43.8%39.3%
3 Year31.4%31.4%-60.5%-60.5%28.6%16.4%
5 Year178.8%178.8%79.5%79.5%58.6%34.7%

Long-Term Price Volatility Vs. Market

How volatile is VentriPoint Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is VentriPoint Diagnostics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether VentriPoint Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as VentriPoint Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is VentriPoint Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

63.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as VentriPoint Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has VentriPoint Diagnostics performed over the past 5 years?

-0.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VPT is currently unprofitable.

Growing Profit Margin: VPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VPT is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.

Accelerating Growth: Unable to compare VPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VPT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (21.2%).


Return on Equity

High ROE: VPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is VentriPoint Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: VPT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VPT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VPT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VPT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VPT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VPT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.6% each year


Dividend

What is VentriPoint Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VPT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

George Adams (68 yo)

1.33yrs

Tenure

CA$201,249

Compensation

Dr. George Adams, B.A.Sc., M.A.Sc., Ph.D., ICD.D., is Managing Director at Cell MedX Corp. He serves as Chief Executive Officer of VentriPoint Diagnostics Ltd. and served as Acting Chief Executive Officer ...


CEO Compensation Analysis

Compensation vs Market: George's total compensation ($USD166.27K) is about average for companies of similar size in the Canadian market ($USD157.18K).

Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: VPT's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: VPT's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VPT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 91.3%.


Top Shareholders

Company Information

VentriPoint Diagnostics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: VentriPoint Diagnostics Ltd.
  • Ticker: VPT
  • Exchange: TSXV
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$57.342m
  • Shares outstanding: 133.35m
  • Website: https://www.ventripoint.com

Location

  • VentriPoint Diagnostics Ltd.
  • 2 Sheppard Avenue East
  • Suite 605
  • Toronto
  • Ontario
  • M2N 5Y7
  • Canada

Listings


Biography

Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System, a med...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/14 22:20
End of Day Share Price2021/05/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.